|
Originally published In Press as doi:10.1074/jbc.M306003200 on October 10, 2003
J. Biol. Chem., Vol. 278, Issue 52, 52131-52138, December 26, 2003
Microsomal Prostaglandin E2 Synthase-1 Is Induced by Conditional Expression of RET/PTC in Thyroid PCCL3 Cells through the Activation of the MEK-ERK Pathway*
Efisio Puxeddu ¶,
Norisato Mitsutake ¶||,
Jeffrey A. Knauf ,
Sonia Moretti ,
Hei W. Kim**,
Karen A. Seta**,
Diane Brockman ,
Leslie Myatt ,
David E. Millhorn**, and
James A. Fagin 
From the
Division of Endocrinology and Metabolism, the **Department of Genome Science, and the  Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 and the Dipartimento di Medicina Interna, University of Perugia, Perugia 06126, Italy
RET/PTC rearrangements are believed to be tumor-initiating events in papillary thyroid carcinomas. We identified microsomal prostaglandin E2 synthase-1 (mPGES-1) as a RET/PTC-inducible gene through subtraction hybridization cloning and expression profiling with custom microarrays. The inducible prostaglandin E2 (PGE2) biosynthetic enzymes cyclooxygenase-2 (COX-2) and mPGES-1 are up-regulated in many cancers. COX-2 is overexpressed in thyroid malignancies compared with benign nodules and normal thyroid tissues. Eicosanoids may promote tumorigenesis through effects on tumor cell growth, immune surveillance, and angiogenesis. Conditional RET/PTC1 or RET/PTC3 expression in PCCL3 thyroid cells markedly induced mPGES-1 and COX-2. PGE2 was the principal prostanoid and up-regulated (by 60-fold), whereas hydroxyeicosatetraenoic acid metabolites were decreased, consistent with shunting of prostanoid biosynthesis toward PGE2 by coactivation of the two enzymes. RET/PTC activated mPGES-1 gene transcription. Based on experiments with kinase inhibitors, with PCCL3 cell lines with doxycycline-inducible expression of RET/PTC mutants with substitutions of critical tyrosine residues in the kinase domain, and lines with inducible expression of activated mutants of H-RAS and MEK1, RET/PTC was found to regulate mPGES-1 through Shc-RAS-MEK-ERK. These data show a direct relationship between activation of a tyrosine kinase receptor oncogene and regulation of PGE2 biosynthesis. As enzymes involved in prostanoid biosynthesis can be targeted with pharmacological inhibitors, these findings may have therapeutic implications.
Received for publication, June 6, 2003
, and in revised form, October 6, 2003.
* This work was supported in part by National Institutes of Health Grant CA50706 (to J. A. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Both authors contributed equally to this work.
|| Supported in part by the Nakayama Foundation for Human Science and Sumitomo Life Social Welfare Services Foundation.
 To whom correspondence should be addressed: Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, P. O. Box 670547, Cincinnati, OH 45267-0547. Tel.: 513-558-4444; Fax: 513-558-8581; E-mail: james.fagin{at}uc.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Croyle, N. Akeno, J. A. Knauf, D. Fabbro, X. Chen, J. E. Baumgartner, H. A. Lane, and J. A. Fagin
RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR
Cancer Res.,
June 1, 2008;
68(11):
4183 - 4191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Samuelsson, R. Morgenstern, and P.-J. Jakobsson
Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target
Pharmacol. Rev.,
September 1, 2007;
59(3):
207 - 224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Santoro, R. M. Melillo, and A. Fusco
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
Eur. J. Endocrinol.,
November 1, 2006;
155(5):
645 - 653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-W. Wang, C.-T. Hsueh, C.-F. J. Lin, T.-Y. Chou, W.-H. Hsu, L.-S. Wang, and Y.-C. Wu
Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non-Small-Cell Lung Cancer
Ann. Surg. Oncol.,
September 1, 2006;
13(9):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Mrozek, R. T. Kloos, M. D. Ringel, L. Kresty, P. Snider, D. Arbogast, M. Kies, R. Munden, N. Busaidy, M. J. Klein, et al.
Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
J. Clin. Endocrinol. Metab.,
June 1, 2006;
91(6):
2201 - 2204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. Ackerman IV, J. M. Robinson, and D. A. Kniss
Despite Transcriptional and Functional Coordination, Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Largely Reside in Distinct Lipid Microdomains in WISH Epithelial Cells
J. Histochem. Cytochem.,
November 1, 2005;
53(11):
1391 - 1401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Puxeddu, J A Knauf, M A Sartor, N Mitsutake, E P Smith, M Medvedovic, C R Tomlinson, S Moretti, and J A Fagin
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response
Endocr. Relat. Cancer,
June 1, 2005;
12(2):
319 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mitsutake, J. A. Knauf, S. Mitsutake, C. Mesa Jr., L. Zhang, and J. A. Fagin
Conditional BRAFV600E Expression Induces DNA Synthesis, Apoptosis, Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells
Cancer Res.,
March 15, 2005;
65(6):
2465 - 2473.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|